Stocktoria
Chemomab Therapeutics Ltd. CMMB
Chemomab Therapeutics Ltd. (CMMB) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CMMB | Chemomab Therapeutics Ltd. | 2/9 | — | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
FAQ
Is CMMB financially healthy?
Chemomab Therapeutics Ltd.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does CMMB pay a dividend?
No, Chemomab Therapeutics Ltd. does not currently pay a dividend.
How profitable is CMMB?
In FY2025, Chemomab Therapeutics Ltd. had a return on equity of -72.9%.
Is CMMB overvalued or undervalued?
Chemomab Therapeutics Ltd. trades at about 106.7× trailing earnings — above its 10-year norm (10-year range 22.4×–326.7×, median 86.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for CMMB?
The average Wall-Street price target for Chemomab Therapeutics Ltd. is $15.00, about 681.3% above the recent price, from 2 analysts.
Is CMMB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Chemomab Therapeutics Ltd.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.